Search | WHO COVID-19 Research Database

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Saini, Kamal S; Lanza, Carlo; Romano, Marco; de Azambuja, Evandro; Cortes, Javier; de Las Heras, Begoña; de Castro, Javier; Lamba Saini, Monika; Loibl, Sibylle; Curigliano, Giuseppe; Twelves, Chris; Leone, Manuela; Patnaik, Mrinal M.

Br J Cancer ; 123(5): 694-697, 2020 09.

Article in English | MEDLINE | ID: covidwho-612104

ABSTRACT

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Subject(s)

Antineoplastic Agents/therapeutic use , Betacoronavirus , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Drug Repositioning/methods , Pneumonia, Viral/drug therapy , Pneumonia, Viral/immunology , Adrenal Cortex Hormones/therapeutic use , Anticoagulants/therapeutic use , Antineoplastic Agents/pharmacology , COVID-19 , Coronavirus Infections/physiopathology , Coronavirus Infections/virology , Humans , Immunologic Factors/therapeutic use , Inflammation/drug therapy , Interleukin-6/antagonists & inhibitors , Pandemics , Pneumonia, Viral/physiopathology , Pneumonia, Viral/virology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Protein Kinase Inhibitors/therapeutic use , SARS-CoV-2 , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitors , COVID-19 Drug Treatment

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL